Business
GALECTIN THERAPEUTICS INC: Animals with the galectin-3 gene "knocked-out" can no longer develop fibrosis in response to experimental stimuli compared to animals with an intact galectin-3 gene.
Net income increased 34.5% to ($30.8M), while Operating cash flow increased 42.8% to ($23.9M).
The read at a glance✓ Audited against SEC data
- Scale — FY2025 revenue N/AWatch
- Profitability — Net income ($30.8M)Watch
- Cash generation — Free cash flow ($23.9M)Note
- Accounting — No applicable forensic screenNote
- Insiders — 4 buys; 37 sells in 365 daysOK
- Capital — Comparable payout data unavailableNote
Leadership changes
From GALECTIN THERAPEUTICS INC's own filings, the day they're filed.
- Henry Brem · member · appointmenteff. 2026-03-12
- Marc Rubin · Directors · departureeff. 2026-01-10
- Seaton Hall University · Chief Medical Officer · appointment
Latest filings
- 8-K · Company announcement2026-08-14
- 10-Q · Quarterly report2026-08-14
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-06-23
- 10-Q · Quarterly report2026-05-15
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about GALECTIN THERAPEUTICS INC, every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.